Leading BioSciences

Leading BioSciences is a clinical-stage, platform pharmaceutical company focused on developing therapies and diagnostics to treat and halt multi-organ failure resulting from shock (sometimes referred to as Multiple Organ Dysfunction Syndrome (MODS)). Our pipeline includes a drug to treat gastrointestinal breakdown resulting from three common forms of shock: cardiogenic shock following heart surgery, septic shock and hemorrhagic shock.

Leading BioSciences’ lead product, LB1148, is the result of over 10 years of research and testing. LB1148 is an investigational drug formulated to preserve gastrointestinal (GI) integrity during shock and halt multi-organ failure or MODS. LB1148 is currently being studied in the SSAIL trial, a multi-center, randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating the efficacy and safety of LB1148 for the treatment of septic shock. Later this year, the company plans to open a 2nd multi-center, randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating the efficacy and safety of LB1148 for the treatment of cardiogenic shock in high-risk cardiovascular surgeries.

Severe, Acute Shock is a life-threatening medical condition with over 1,300,000 cases and over 500,000 deaths in the U.S. annually. Globally, severe shock and multi-organ failure kills over 2,000,000 people annually. LB1148 may be used for the treatment of cardiovascular surgeries which can result in systemic hypoperfusion and cardiogenic shock, septic shock in severe sepsis cases, and trauma or heavy blood loss, which can lead to extremely low blood pressure and hypovolemic or hemorrhagic shock. Each of these represents large patient populations with high unmet medical need due to long term morbidity and high mortality rates.

Gastrointestinal breakdown contributes to disease in approximately 20 to 30 million people on a yearly basis. To develop that pipeline, LBS has established a world-class management team, as well as medical advisory panels, qualified to bring multiple blockbusters to the global marketplace to successfully address the adverse effects of this mechanism.